MAPK3 and breast cancer: While Erk1/2 phosphorylation was unaffected, nearly complete inhibition of Akt phosphorylation was observed with the combination of dasatinib and BMS-754807.These findings are in keeping with recent data showing in breast cancer that Erk1/2 phophorylation is not mediated by IGF-1, but rather insulin and IGF-2 [49].